Patient Services and Hub Solutions for Life Sciences: Ensuring Specialty Product Access and Market Entry, Optimizing Outcomes for Rare Disease Patients

The AscellaHealth Business Development Team will be attending Asembia’s Specialty Pharmacy Summit*, in Las Vegas, May 2-5, 2022. Click here to schedule a meeting with AscellaHealth in Las Vegas.*

The rare disease community is gaining attention around the world, shining a light on the challenges and barriers to accessing care that face these patients. Two of the biggest issues for many specialty patients is the impact of a delayed or missed diagnosis, and heavy social and financial difficulties that burden patients and their families.

The true costs of care for rare patients are difficult to determine due to information gaps, lack of specific diagnostic tests, delayed diagnosis or missed diagnosis, and the absence of specific ICD-10 codes and treatments. Also, many fragmented non-medical and indirect costs of care are spread across patients, families and communities.

An estimated 300 million patients worldwide have diagnoses related to 7,000 unique rare diseases. More than 70% of these diseases are genetic in origin. With scientific advances bringing more treatments to market, the time has come for manufacturers to ensure that patient and caregiver needs are being met to hasten the diagnosis process, enhance the patient journey and improve compliance.

Medication adherence can have a more direct impact on patient outcomes than the specific treatment itself, which is why a patient-first approach is so vital for keeping patients on track with their treatment plan.

Benefits of Patient-First Approach

Specialty patients require a high level of therapy adherence support, targeted programs and services that deliver specialized expertise, transcending the traditional care continuum provided by legacy organizations that are simply built for scale.

An innovative, patient-first approach allows patients, providers and care coordinators to connect effortlessly, rather than operating independently to deliver fragmented care. Such high-level care coordination strengthens communication, yields rich data for more informed decision-making and improves the overall patient experience. This approach also empowers clinical teams to seamlessly eliminate treatment gaps for the patient.

For specialty pharmaceutical manufacturers, greater focus on specialty drugs helps to ensure that products are readily accessed by prescribed patients, and that drug therapy is monitored for effectiveness, compliance and adherence to treatment. For specialty patients, it is critically important to consider the continued utilization and rising costs of specialty agents, rise in biosimilars and other specialty agents, and more focused management involving patient-first partnerships that ensure adherence to treatment.

AscellaHealth’s Patient-First Approach

At AscellaHealth, our focus is the appropriate delivery and management of specialty drugs, the key components of our patient-first approach to caring for patients with rare disease. Every care decision is based on what is best for the patient.

To serve the needs of both patients and pharmaceutical companies, AscellaHealth offers a full spectrum of cutting-edge programs and services that include:

• Pre-Commercialization and Outsourced Market Access
• National LDD Fulfillment Capabilities
• Distribution, Wholesale, and 3PL Services
• Comprehensive HUB and Patient Support Services
• Streamlined Prior Authorizations
• Technology-based Patient Engagement
• Copay and Financial Assistance Programs
• Real-time Rx Data and Analytics
• Drug Rebate Programs

These innovative solutions ensure products are successfully brought to market, while optimizing

outcomes and the patient journey.

Partnerships for Success

It is advantageous for pharmaceutical manufacturers to align with a patient-first, pharmacy-first Hub provider, like AscellaHealth. These partnerships translate into a true collaborative approach that is backed by a team with a thorough understanding of the payer mix and value across multiple specialty categories.

Our management team has deep-bench experience and expertise in payer reimbursement and strategy development, in-depth understanding of the competitive environment, and knowledge of key programs needed to drive branded volume. Collectively, these programs result in optimal patient access to products in major specialty and rare disease categories.

With a goal to ensure that patients can seamlessly access medications and obtain the high touch support they need, we also offer a robust suite of services that include: customized clinical support programs and interventions that result in improved compliance to therapy; distribution partnerships and national fulfillment of specialty medications; as well as high-touch and technology-backed capabilities to further improve the patient experience and enhance clinical outcomes.

Ultimately, AscellaHealth’s patient-first approach offers a more “human touch” for people facing chronic illness and uncertainty, while exceeding the limitations of the retail pharmacy approach. Our end-to-end solutions impact the lives of individuals with rare disease and keep the patient as the central point of focus in everything we do.

AscellaHealth will be attending Asembia’s Specialty Pharmacy Summit, Las Vegas, May 2-5, 2022. To schedule a meeting please reach out to businessdevelopment@ascellahealth.com.